32.82
전일 마감가:
$31.68
열려 있는:
$31.42
하루 거래량:
370.23K
Relative Volume:
0.71
시가총액:
$1.77B
수익:
$651.97M
순이익/손실:
$59.71M
주가수익비율:
30.68
EPS:
1.0696
순현금흐름:
$172.03M
1주 성능:
+1.64%
1개월 성능:
+2.50%
6개월 성능:
+2.18%
1년 성능:
-0.93%
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
명칭
Supernus Pharmaceuticals Inc
전화
301-838-2500
주소
9715 KEY WEST AVENUE, ROCKVILLE, MD
SUPN을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
SUPN
Supernus Pharmaceuticals Inc
|
32.82 | 1.77B | 651.97M | 59.71M | 172.03M | 1.0696 |
![]()
ZTS
Zoetis Inc
|
163.46 | 72.50B | 9.26B | 2.49B | 2.30B | 5.47 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.97 | 47.08B | 30.25B | 1.37B | 5.08B | 0.4257 |
![]()
HLN
Haleon Plc Adr
|
10.16 | 45.99B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.29 | 17.38B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
ITCI
Intra Cellular Therapies Inc
|
0.00 | 14.05B | 612.78M | -86.37M | -62.91M | -0.87 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-02-19 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
2025-01-06 | 개시 | Cantor Fitzgerald | Overweight |
2024-09-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
2023-01-03 | 재개 | Jefferies | Buy |
2021-12-01 | 재개 | Jefferies | Buy |
2021-04-13 | 업그레이드 | Jefferies | Hold → Buy |
2020-06-16 | 업그레이드 | Piper Sandler | Neutral → Overweight |
2020-06-15 | 재개 | Jefferies | Hold |
2019-11-08 | 다운그레이드 | Berenberg | Buy → Hold |
2019-11-07 | 다운그레이드 | Stifel | Buy → Hold |
2019-11-06 | 다운그레이드 | Jefferies | Buy → Hold |
2018-11-12 | 재확인 | B. Riley FBR | Buy |
2018-01-18 | 재확인 | B. Riley FBR, Inc. | Buy |
2017-12-28 | 재확인 | B. Riley FBR, Inc. | Buy |
2017-12-04 | 업그레이드 | Janney | Neutral → Buy |
2017-11-08 | 업그레이드 | Stifel | Hold → Buy |
2017-10-19 | 개시 | FBR & Co. | Buy |
2017-09-19 | 다운그레이드 | Stifel | Buy → Hold |
2017-07-17 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
2017-07-14 | 개시 | Janney | Neutral |
2017-06-01 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
2016-07-18 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
2016-07-18 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
2016-02-08 | 업그레이드 | Jefferies | Hold → Buy |
2015-11-05 | 재확인 | Northland Capital | Outperform |
2015-10-28 | 개시 | Northland Capital | Outperform |
모두보기
Supernus Pharmaceuticals Inc 주식(SUPN)의 최신 뉴스
Several Supernus Pharmaceuticals Insiders Sell Shares Sending Potential Negative Signal - simplywall.st
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Bought by HighTower Advisors LLC - Defense World
Supernus Pharmaceuticals (NASDAQ:SUPN) Upgraded by StockNews.com to “Strong-Buy” Rating - Defense World
An Investigation Has Commenced on Behalf of Supernus Pharmaceuticals, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your SUPN Losses. - ACCESS Newswire
Thrivent Financial for Lutherans Sells 591 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Teacher Retirement System of Texas Has $591,000 Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
ATTENTION SUPN SHAREHOLDERS: Investors who lost money on Supernus Pharmaceuticals, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation - ACCESS Newswire
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Acquired by Swiss National Bank - Defense World
Supernus Pharmaceuticals (NASDAQ:SUPN) Downgraded to “Buy” Rating by StockNews.com - Defense World
11,282 Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Acquired by Proficio Capital Partners LLC - Defense World
Supernus Pharmaceuticals, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Supernus Pharmaceuticals, Inc. (SUPN) - ACCESS Newswire
Raymond James Financial Inc. Takes $6.85 Million Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Raymond James Financial Inc. Invests $6.85 Million in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Armenian Reporter
(SUPN) Trading Report - news.stocktradersdaily.com
SUPN ACTIVE INVESTIGATION: Contact Levi & Korsinsky if You Lost Money on Your Supernus Pharmaceuticals, Inc. Investment - ACCESS Newswire
PNC Financial Services Group Inc. Sells 362 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Atria Investments Inc Invests $288,000 in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Charles Schwab Investment Management Inc. Purchases 40,968 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Down -20.07% in 4 Weeks, Here's Why Supernus (SUPN) Looks Ripe for a Turnaround - Yahoo Finance
Supernus Pharmaceuticals (NASDAQ:SUPN) Upgraded to “Strong-Buy” at StockNews.com - Defense World
Q4 Earnings Recap: Supernus Pharmaceuticals (NASDAQ:SUPN) Tops Branded Pharmaceuticals Stocks - Yahoo Finance
Bank of New York Mellon Corp Boosts Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Where are the Opportunities in (SUPN) - news.stocktradersdaily.com
Smartleaf Asset Management LLC Has $47,000 Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Lost Money on Supernus Pharmaceuticals, Inc. (SUPN)? You May Have Been Affected by FraudContact Levi & Korsinsky - ACCESS Newswire
Proficio Capital Partners LLC Acquires Shares of 11,282 Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Rating Lowered by StockNews.com - Defense World
Supernus Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Spectrum Brands Holdings, Inc. (SPB): Among the Cash-Rich Small Cap Stocks To Invest In According To Analysts - Insider Monkey
Supernus Pharmaceuticals, Inc. (SUPN): Among the Cash-Rich Small Cap Stocks To Invest In According To Analysts - Insider Monkey
Supernus to Participate in Two Upcoming Investor Conferences - GlobeNewswire
CNS Specialist Supernus Sets Investor Conference ScheduleWill You Hear What the CEO Has to Say? - StockTitan
Lost Money on Supernus Pharmaceuticals, Inc.(SUPN)? You May Have Been Affected by FraudContact Levi & Korsinsky - ACCESS Newswire
An Investigation Has Commenced on Behalf of Supernus Pharmaceuticals, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your SUPN Losses - accessnewswire.com
Does The Market Have A Low Tolerance For Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Mixed Fundamentals? - Yahoo Finance
Is Supernus Pharmaceuticals, Inc. (SUPN) the Best Small Cap Pharma Stock to Buy Now? - Insider Monkey
Is Supernus Pharmaceuticals, Inc. (SUPN) the Best Small Cap Pharma Stocks to Buy Now? - Yahoo Finance
(SUPN) Technical Data - Stock Traders Daily
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Bought by Principal Financial Group Inc. - Defense World
Supernus Pharmaceuticals’ (SUPN) “Neutral” Rating Reiterated at Cantor Fitzgerald - Defense World
StockNews.com Downgrades Supernus Pharmaceuticals (NASDAQ:SUPN) to Buy - Defense World
Decoding Supernus Pharmaceuticals Inc (SUPN): A Strategic SWOT I - GuruFocus.com
12 Best Small Cap Pharma Stocks to Buy Now - Insider Monkey
Supernus Pharmaceuticals’ Earnings Call Highlights Growth and Challenges - TipRanks
Supernus to Participate in the TD Cowen 45th Annual Health Care Conference - GlobeNewswire
What Questions Should Investors Ask Supernus CEO at Upcoming TD Cowen Conference? - StockTitan
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stake Boosted by Rhumbline Advisers - Defense World
Supernus Pharmaceuticals (SUPN) Beats Q4 Earnings and Revenue Estimates - MSN
Supernus Pharmaceuticals Enters Oversold Territory (SUPN) - Nasdaq
Supernus Pharmaceuticals Inc (SUPN) Reports Q4 2024 EPS of $0.27 - GuruFocus.com
Cantor maintains neutral on Supernus, price target at $36 By Investing.com - Investing.com South Africa
Supernus Pharmaceuticals Inc (SUPN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Supernus Pharmaceuticals Inc 주식 (SUPN) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
DEC TIMOTHY C | Senior Vice-President & CFO |
Mar 10 '25 |
Option Exercise |
0.00 |
3,800 |
0 |
13,636 |
Khattar Jack A. | President, CEO |
Mar 07 '25 |
Option Exercise |
0.00 |
38,640 |
0 |
992,219 |
Mottola Frank | SVP, Quality, GMP, Ops, IT |
Mar 07 '25 |
Option Exercise |
0.00 |
2,625 |
0 |
16,507 |
Mottola Frank | SVP, Quality, GMP, Ops, IT |
Feb 26 '25 |
Option Exercise |
0.00 |
5,760 |
0 |
17,683 |
Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Feb 21 '25 |
Option Exercise |
0.00 |
1,650 |
0 |
11,799 |
Rubin Jonathan | SVP, Chief Medical Officer |
Feb 21 '25 |
Option Exercise |
0.00 |
1,875 |
0 |
8,780 |
Rubin Jonathan | SVP, Chief Medical Officer |
Feb 21 '25 |
Sale |
39.15 |
927 |
36,292 |
7,853 |
Mottola Frank | SVP, Quality, GMP, Ops, IT |
Feb 21 '25 |
Option Exercise |
0.00 |
1,125 |
0 |
9,576 |
Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Feb 04 '25 |
Option Exercise |
29.61 |
9,477 |
280,614 |
19,626 |
Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Feb 04 '25 |
Sale |
39.70 |
9,477 |
376,237 |
10,149 |
자본화:
|
볼륨(24시간):